| 杨琼 王璐 周霞 时永全 韩英△.原发性胆汁性肝硬化患者血清IL-6 水平与UDCA疗效的相关性研究[J].现代生物医学进展英文版,2016,16(15):2855-2859. |
| 原发性胆汁性肝硬化患者血清IL-6 水平与UDCA疗效的相关性研究 |
| A Correlation Study on SerumIL-6 Level in Primary Biliary Cirrhosis withClinical Efficacy of UDCA |
| |
| DOI： |
| 中文关键词: 原发性胆汁性肝硬化 熊去氧胆酸 白介素-6 |
| 英文关键词: Primary biliary cirrhosis Ursodeoxycholic acid IL-6 |
| 基金项目:国家自然科学基金面上项目（81370519，81170372，81470835） |
|
| Hits: 937 |
| Download times: 0 |
| 中文摘要: |
| 目的：观察原发性胆汁性肝硬化（primary biliary cirrhosis, PBC)患者治疗前后血清IL-6 表达水平，探索其与熊去氧胆酸（Ursodeoxycholic
acid, UDCA）疗效的临床相关性。方法：本研究回顾性纳入自2013 年-2015 年就诊于第四军医大学西京消化病医院
的40 例新诊断PBC 患者，及40 例健康对照者。收集PBC 患者治疗前后的相关临床资料和血清样本，采用ELISA 方法检测患者
血清IL-6 表达水平，并进一步分析其临床意义。结果：1）治疗前PBC患者血清IL-6 表达水平明显高于健康对照者(P<0.001)；2）
PBC 患者在接受UDCA 治疗后的第3，6 和12 个月血清IL-6 水平与治疗前相比明显降低(P<0.05)，且在第3 个月时下降最明显。
3）无论是依据Paris I标准还是Barcelona 标准，结果显示，UDCA 应答者与应答不佳者相比其治疗前血清IL-6 水平无统计学差异
（P=0.373；P=0.409）。但UDCA 应答者在治疗3 个月时其血清IL-6 表达水平比治疗前明显下降(P<0.05)，而应答不佳者治疗3 个
月时血清IL-6 表达水平与治疗前相比无明显差异（P=0.667；P=0.186）。结论：IL-6 可能在PBC 发病的免疫机制中发挥着重要的作
用。目前尚不能认为PBC 患者治疗前血清IL-6 表达水平能独立评价UDCA疗效，但是治疗三个月后患者血清IL-6 水平下降趋
势能够提示PBC 患者对UDCA 的应答情况。 |
| 英文摘要: |
| Objective:To observe the serum IL-6 levels in patients with primary biliary cirrhosis (PBC) and explore the association
between the serum IL-6 levels with the therapeutic effects of Ursodeoxycholic acid (UDCA).Methods:40 PBC patients and 40
healthy individuals who were visited the Xijing Hospital of Digestive Diseases between 2013 and 2015 were included in our study. Their
clinical data and serum samples were selected for research. The serum levels of IL-6 were measured by ELISA and the results were further
analyzed.Results:1) The basal serum level of IL-6 in PBC patients was significantly higher than that of healthy controls (P<0.001).
2) After treatment with UDCA, the serum IL-6 levels in the third month, the sixth month and the twelfth months all showed remarkable
decrease when compared to their basal levels (P<0.05). Besides, the decline in the third month was the most obvious. 3) The results
showed no significant difference of the basal serumIL-6 levels between UDCA responders and UDCA non-responders according to Paris
I criteria or Barcelona criteria(P=0.373; P=0.409). However, the serum IL-6 level of UDCA responders showed significant decrease after
treatment for 3 months (P<0.05), while UDCA non-responders demonstrated no difference in the third months after UDCA treatment
(P=0.667; P=0.186).Conclusion:IL-6 may play a significant role in the immunologic mechanism of PBC. The decline of serum IL-6
levels may contribute to prompt the therapeutic effects of UDCA, but we could not assess the subsequent response to UDCA by the
serumIL-6 levels independently. |
|
View Full Text
View/Add Comment Download reader |
| Close |
